BCR-ABL-IN-10 (compound B4) is a covalent BCR-ABL inhibitor featuring an arylvinylsulfonate (AVS) moiety, demonstrating an IC50 of 43.1 nM against ABL kinase. It forms a covalent and stable adduct with ABL kinase, enabling the sustained inhibition of intrinsic BCR-ABL activity. This compound is utilized in the study of chronic myeloid leukemia (CML).
Molecular Weight:
478.52
Formula:
C24H22N4O5S
Target:
Bcr-Abl
T200894
* VAT and and shipping costs not included. Errors and price changes excepted
